HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics

HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics

Abstract Background Therapies targeting anti-tumor T-cell responses have proven successful in the treatment of a variety of malignancies. However, as most patients still fail to respond, approaches to augment immunotherapeutic efficacy are needed. Here, we investigated the ability of histone deacety...

Full description

Bibliographic Details
Main Authors: Andressa S. Laino, B. C. Betts, A. Veerapathran, I. Dolgalev, A. Sarnaik, S. N. Quayle, S. S. Jones, J. S. Weber, David M. Woods
Format: Article
Language:English
Published: BMJ Publishing Group 2019-02-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
HDAC inhibitor
HDAC6
ACY-1215
ACY-241
Melanoma
T-cells
Online Access:http://link.springer.com/article/10.1186/s40425-019-0517-0

Internet

http://link.springer.com/article/10.1186/s40425-019-0517-0

Similar Items